**Wake Forest NCORP Research Base**

**Bi-Weekly Broadcast**

**February 18, 2019**

**Reminders:**

* **6th Annual NCORP meeting November 14 – 16** in Greenville, SC at the Hyatt Regency.
* WF NCORP still requires HSP and GCP in order to obtain REDCap access.
* If you require Specimen kits for your studies, please send your request form to the lab at the following email address: 7NCORP@wakehealth.edu
* **REDCap Upgrade that will affect WF20817CD – OASIS, WF10217 – WAYS, WF1803CD – CAREGIVERS, and EAQ161CD** – Beginning at 8 AM ET on Wednesday, February 20, the Wake Forest REDCap will be down for a system-wide upgrade. The upgrade is expected to take approximately 1 hour. During that time, all data entry and survey instruments will be inaccessible.
* **WF 01213 – Relax** – If you are a participating site for this study, please send in your devices and other equipment for this study if you do not have plans to enroll someone as we have sites that need this equipment.
* **WF 97115 – Acupuncture** – We would like to give a shout out to Kaiser Permanente who is now on board and actively recruiting to this study. Please let us know if you have any barriers to recruitment or suggestions for improvement. We would like to thank Dr. Kay Garcia who is retiring from MD Anderson as of February 28, 2019 after 15 years of service. NCORP truly appreciates your hard work and have enjoyed working with you through the years.
* **WF 1803CD - Caregivers, Version Date 10/23/2018, Activated 12/10/2018**

The Wake Forest NCORP RB is pleased to announce the activation of **WF-1803CD--Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices**. This CCDR study will accrue oncology providers and supportive care leads at participating NCORP affiliates and sub affiliates. Approved protocol documents are posted on the CTSU website.

Please note, the CIRB is not requiring that NCORP sites seek approval to participate in this study; local NCORP staff will not be directly recruiting or consenting participants. An amendment is currently being submitted to make minor clarifying corrections, but this will not impact the initial steps of study participation (1: indicating the interest and possible grouping of affiliates/sub-affiliates and 2: confirming their eligibility). If you choose to seek local IRB approval (which is not required), you might consider submitting your documents until after Amendment 1 has been approved (estimated in early February). We look forward to working with our NCORP members on this exciting study which will provide critical information about how to best engage cancer caregivers in oncology care settings.

* **EAQ161CD – Biomarker Testing in Common Solid Cancers: An Assessment of Current Practices in Precision Oncology in the Community Setting**
* This study is being conducted by an ECOG-ACRIN investigator team. It involves a survey being sent to specific sites on biomarker testing practices in Lung, Colorectal, Breast and Melanoma cancers.
* The goal is to inform NCORP sites, and the cancer care community at large, how biomarker testing is conducted. Anonymous, un-attributable report of findings will be shared with all responding NCORP sites, components and subcomponents.
* Responses will be kept strictly confidential.
* This study has been reviewed by the Central IRB, which determined that this study does not constitute Human Subjects Research as defined by 45 CFR 46.
* The 43 adult NCORP PIs and CCDR Leads will be sent an invitational email explaining registration procedures. If you have questions about the study, please contact Julia Trosman, PhD at trosman@centerforbusinessmodels.com
* There will be a Training Webinar offered two times. The access information is the same for both EAQ161CD Training Webinars:
1. **Wed 3/13/2019 at 1 pm ET**
2. **Tues 3/26/2019 at 10 am ET**

Please join my meeting from your computer, tablet or smartphone.
[https://global.gotomeeting.com/join/471383285 [global.gotomeeting.com]](https://urldefense.proofpoint.com/v2/url?u=https-3A__global.gotomeeting.com_join_471383285&d=DwMFAg&c=yzGiX0CSJAqkDTmENO9LmP6KfPQitNABR9M66gsTb5w&r=tngVBjW8oDqwtNTRyd51D9bn8ffMNkCXyt0LOyIDHnM&m=LANE6GtxBYsfiSha-Dv9qzewxPWsklhdvhDtjtjEAIE&s=WJDZ8Cf9WL0LOj5SClMdSYyK577bIWeLEwbm23VxSD4&e=)

You can also dial in using your phone.
(For supported devices, tap a one-touch number below to join instantly.)

United States: +1 (408) 650-3123
- One-touch: tel:+14086503123,,471383285#

Access Code: 471-383-285

Joining from a video-conferencing room or system?
Dial: 67.217.95.2##471383285
Cisco devices: 471383285@67.217.95.2

First GoToMeeting? Let's do a quick system check: [https://link.gotomeeting.com/system-check [link.gotomeeting.com]](https://urldefense.proofpoint.com/v2/url?u=https-3A__link.gotomeeting.com_system-2Dcheck&d=DwMFAg&c=yzGiX0CSJAqkDTmENO9LmP6KfPQitNABR9M66gsTb5w&r=tngVBjW8oDqwtNTRyd51D9bn8ffMNkCXyt0LOyIDHnM&m=LANE6GtxBYsfiSha-Dv9qzewxPWsklhdvhDtjtjEAIE&s=6g0PWgoVjgzffJzajYgBtICnXeFXNKJSSXFngqgM8Z4&e=)

* **WAYS WF-10217 – Amendment 3 – Effective 1/21/19, all Strata open once again for additional participants Each Strata will now accrue 55 to each. The number of participants enrolled has changed to account for those participants who are being replaced.**
* **Enrollment is now restricted to racial/ethnic minority participants**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **STRATUM** | **PARTICIPANTS ENROLLED** | **AGE** | **TIME SINCE ORIGINAL CANCER DIAGNOSIS** | **NOTES** |
| A | 49 | 25-29 | 2 years to < 6 years | Still accruing |
| B | 46 | 25-29 | 6 years to < 10 years | Still accruing |
| C | 53 | 30-34 | 2 years to < 6 years | Still accruing |
| D | 47 | 30-34 | 6 years to < 10 years | Still accruing |

**WF 1802 PCW**

The Wake Forest NCORP Research Base has a new study (WF-1802: *Influence of Primary Treatment for Prostate Cancer on Work Experience* (PCW)) that we expect to activate later this Spring. An introductory webinar will be announced soon.

Briefly, we plan to examine how prostate cancer treatment affects African American men’s ability to work. We will enroll 220 people in the study, stratified by race (African American, non-Hispanic; white, non-Hispanic) and income (low income, moderate to high income). Participants will be interviewed a total of three times – before treatment begins, 3 months after treatment, and 6 months after treatment. Each interview will last approximately 40-60 minutes and will include questions about participants’ job and workplace, medical leave from work, symptoms associated with prostate issues, and physical and mental well-being.



**Current Accruals as of 02/18/19**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study Title** | **Study Number** | **Accrual** | **Target** |
| RELAX | 01213 | 36 | 75 |
| WAYS | 10217 | 195 | 200 |
| ACUPUNCTURE | 97115 | 180 | 240 |
| REMEMBER | 97116 | 144 | 276 |
| UPBEAT | 97415 | 147 | 1000 |
| OaSiS | 20817 | 497 | 1114 |
| Telehealth | 30917 | 8 | 90 |